Showing results (191-200 of 344) with videos related to
Sort By:
Pageof 35
Head & Neck|October 2, 2014
Presence of anaplastic lymphoma kinase translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case seriesSung Min Kim, Moon Jin Kim, Hyun Ae Jung, et al.Journal for Immunotherapy of Cancer|February 14, 2023
Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatmentHyunsu Kim, Sehhoon Park, Kyoung-Yeon Han, et al.Frontiers in Oncology|November 7, 2024
Clinical utility of circulating tumor DNA profiling in detecting targetable fusions in non-small cell lung cancerYoung-Gon Kim, Boram Lee, Changhee Ha, et al.World Neurosurgery|August 28, 2016
Outcomes of Gamma Knife Radiosurgery in Combination with Crizotinib for Patients with Brain Metastasis from Non-Small Cell Lung CancerJung Won Choi, Doo-Sik Kong, Ho Jun Seol, et al.The Korean Journal of Internal Medicine|June 20, 2018
Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neckMoon Jin Kim, Sung Min Kim, Hyun Ae Jung, et al.Cancer Research and Treatment|February 18, 2015
Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung CancerJae Myoung Noh, Yong Chan Ahn, Hyebin Lee, et al.Lung Cancer (Amsterdam, Netherlands)|August 14, 2009
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancerJong-Mu Sun, Do-Youn Oh, Se-Hoon Lee, et al.Journal of Cancer Research and Clinical Oncology|June 1, 2011
Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancySoohyeon Lee, Youngwook Kim, Jong-Mu Sun, et al.Cancer Medicine|April 19, 2022
Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitorsMinsuk Kwon, Bo Mi Ku, Steve Olsen, et al.Urologic Oncology|December 24, 2013
FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapyJi-Youn Sung, Jong-Mu Sun, Byong Chang Jeong, et al.Pageof 35